Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1

Carcinogenesis

Volumn 31, Issue 9, 2010, Pages 1604-1611

  Slattery, Martha L ^a   Herrick, Jennifer S ^a   Lundgreen, Abbie ^a   Fitzpatrick, Francis A ^b   Curtin, Karen ^a   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; FK 506 BINDING PROTEIN; FK506 BINDING PROTEIN 12 RAPAMYCIN ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHORYLATES THE ADENOSINE MONOPHOSPHATE DEPENDENT KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; TSC1 PROTEIN; TUBERIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RECTUM CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

ADULT; AGED; AMP-ACTIVATED PROTEIN KINASES; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECTAL NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 77956288187     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq142     Document Type: Article

References (48)

1. Slattery, M.L. et al. (2009) Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev. Res. (Phila. Pa), 2, 922-930.
2. Caan, B.J. et al. (1998) Body size and the risk of colon cancer in a large case-control study. Int. J. Obes. Relat. Metab. Disord., 22, 178-184.
3. Slattery, M.L. et al. (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control, 14, 75-84.
4. Slattery, M.L. et al. (2003) Physical activity and colorectal cancer. Am. J. Epidemiol., 158, 214-224.
5. Slattery, M.L. et al. (1997) Energy balance and colon cancer-beyond physical activity. Cancer Res., 57, 75-80.
6. Kampman, E. et al. (1997) Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control, 8, 146-158.
7. Slattery, M.L. et al. (2004) Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol. Biomarkers Prev., 13, 538-545.
8. Camp, N.J. et al. (2002) Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control, 13, 813-823.
9. Esteller, M. et al. (2000) Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene, 19, 164-168.
10. Shen, Z. et al. (2002) The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin. Cancer Res., 8, 2085-2090.
11. Carling, D. (2004) AMPK. Curr. Biol., 14, R220.
12. Hardie, D.G. (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 144, 5179-5183.
13. Carling, D. (2004) The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci., 29, 18-24.
14. Viollet, B. et al. (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans., 31, 216-219.
15. Woods, A. et al. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol., 13, 2004-2008.
16. Hawley, S.A. et al. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMPactivated protein kinase cascade. J. Biol., 2, 28.
17. Shaw, R.J. et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA, 101, 3329-3335.
18. Menon, S. et al. (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene, 27 (suppl 2), S43-S51.
19. Pilarski, R. et al. (2004) Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J. Med. Genet., 41, 323-326.
20. Agarwal, A. et al. (2005) The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene, 24, 1021-1031.
21. Edwards, S. et al. (1994) Objective system for interviewer performance evaluation for use in epidemiologic studies. Am. J. Epidemiol., 140, 1020-1028.
22. Slattery, M.L. et al. (1994) A computerized diet history questionnaire for epidemiologic studies. J. Am. Diet. Assoc., 94, 761-766.
23. Carlson, C.S. et al. (2004) Selecting a maximally informative set of singlenucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet., 74, 106-120.
24. Hochberg, Y. et al. (1990) More powerful procedures for multiple significance testing. Stat. Med., 9, 811-818.
25. Samowitz, W.S. et al. (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer, 99, 597-602.
26. Slattery, M.L. et al. (2000) Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J. Natl Cancer Inst., 92, 1831-1836.
27. Samowitz, W.S. et al. (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev., 9, 1193-1197.
28. Slattery, M.L. et al. (2007) Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int. J. Cancer, 120, 656-663.
29. Zheng, G. et al. (2006) On estimation of the variance in Cochran-Armitage trend tests for genetic association using case-control studies. Stat. Med., 25, 3150-3159.
30. Shephard, N.D. et al. (2009) A breast cancer risk haplotype in the caspase-8 gene. Cancer Res., 69, 2724-2728.
31. Conneely, K.N. et al. (2007) So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am. J. Hum. Genet., 81, 1158-1168.
32. Curtin, K. et al. (2009) Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol. Biomarkers Prev., 18, 3384-3388.
33. Slattery, M.L. et al. (2009) Tumor markers and rectal cancer: support for an inflammation-related pathway. Int. J. Cancer, 125, 1698-1704.
34. Slattery, M.L. et al. (2009) A comparison of colon and rectal somatic DNA alterations. Dis. Colon Rectum, 52, 1304-1311.
35. Fisher, T.L. et al. (2004) Signaling pathways: the benefits of good communication. Curr. Biol., 14, R1005-R7.
36. Mak, B.C. et al. (2003) The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J. Biol. Chem., 278, 5947-5951.
37. Hardie, D.G. (2004) The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci., 117, 5479-5487.
38. Xu, M. et al. (2005) Glucose and lipid metabolism in relation to novel polymorphisms in the 5'-AMP-activated protein kinase gamma2 gene in Chinese. Mol. Genet. Metab., 86, 372-378.
39. Shaw, R.J. et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91-99.
40. Alessi, D.R. et al. (1998) The role of PI 3-kinase in insulin action. Biochim. Biophys. Acta, 1436, 151-164.
41. DeGraffenried, L.A. et al. (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol., 15, 1510-1516.
42. Vivanco, I. et al. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
43. Lee, D.F. et al. (2007) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle, 6, 3011-3014.
44. Lee, D.F. et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell, 130, 440-455.
45. Cook, W.D. et al. (2000) Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene, 19, 3434-3438.
46. Wagner, T.M. et al. (2006) Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11: cyclopentenone prostaglandins and 4-hydroxy-2-nonenal covalently modify and inhibit the AMP-kinase kinase that modulates cellular energy homeostasis and protein translation. J. Biol. Chem., 281, 2598-2604.
47. Covey, T.M. et al. (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene, 26, 5784-5792.
48. Slattery, M.L. et al. (2003) Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr. Cancer, 46, 166-171.